First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

IE Smith; JY Pierga; L Biganzoli; P Kellokumpu-Lehtinen

doi:10.1093/annonc/mdq430

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

IE Smith, JY Pierga, L Biganzoli, P Kellokumpu-Lehtinen

Research output: Contribution to journal › Article › Scientific › peer-review

105 Citations (Scopus)

Original language	English
Pages (from-to)	595-602
Journal	Annals of Oncology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1093/annonc/mdq430
Publication status	Published - 2011
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdq430

Cite this

@article{850633b34c704cf7bf3b4a90b87df495,

title = "First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients",

author = "IE Smith and JY Pierga and L Biganzoli and P Kellokumpu-Lehtinen",

year = "2011",

doi = "10.1093/annonc/mdq430",

language = "English",

volume = "22",

pages = "595--602",

number = "3",

}

TY - JOUR

T1 - First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

AU - Smith, IE

AU - Pierga, JY

AU - Biganzoli, L

AU - Kellokumpu-Lehtinen, P

PY - 2011

Y1 - 2011

U2 - 10.1093/annonc/mdq430

DO - 10.1093/annonc/mdq430

M3 - Article

SN - 1569-8041

VL - 22

SP - 595

EP - 602

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -